Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Revenue (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Revenue for 5 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 36.87% to $57.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.8 million through Dec 2025, up 45.83% year-over-year, with the annual reading at $189.8 million for FY2025, 45.83% up from the prior year.
  • Revenue for Q4 2025 was $57.3 million at Rhythm Pharmaceuticals, up from $51.3 million in the prior quarter.
  • The five-year high for Revenue was $57.3 million in Q4 2025, with the low at -$8.0 million in Q4 2022.
  • Average Revenue over 5 years is $20.4 million, with a median of $20.9 million recorded in 2023.
  • Peak annual rise in Revenue hit 4180.0% in 2022, while the deepest fall reached 542.93% in 2022.
  • Over 5 years, Revenue stood at $1.8 million in 2021, then crashed by 542.93% to -$8.0 million in 2022, then skyrocketed by 401.12% to $24.2 million in 2023, then skyrocketed by 72.61% to $41.8 million in 2024, then soared by 36.87% to $57.3 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $57.3 million, $51.3 million, and $48.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.